Ginkgo Bioworks Holdings Inc. (DNA, Financial) experienced a significant stock movement, rising by 5.06% with the latest stock price at $8.10. The trading volume reached 435,870 shares, reflecting a turnover rate of 0.78% and a volatility of 7.52%.
According to recent financial reports, Ginkgo Bioworks recorded a revenue of $56.21 million, a net loss of $217 million, and earnings per share of -$4.23. The gross profit stood at $25.16 million with a price-to-earnings ratio of -0.45. Among the six institutions that rated the stock, 17% recommended a buy, another 17% suggested holding, while 66% advised selling.
The biotechnology sector, in which Ginkgo Bioworks operates, saw an overall decline of 1.71%. Within this sector, stocks like Elevai Labs Inc., Theriva Biologics Inc., and Geovax Labs Inc. showed notable increases. Theriva Biologics and Aditxt Inc. displayed high activity levels, with turnover rates of 5473.67% and 1672.28%, respectively. Stocks with significant volatility included Psyence Biomedical Ltd, Elevai Labs, and Seastar Medical Holding Corp.
Ginkgo Bioworks Holdings Inc. specializes in a cell programming platform, offering end-to-end services to markets such as food, agriculture, pharmaceuticals, and chemicals. The company has two main business segments: Foundry and Biosecurity, with most revenue generated from the biosecurity division through data analysis and services.
